Supplementary Figure S1 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Year: 2026
Type: supplementary-materials
Abstract: Supplementary Figure S1 shows boxplots of gastric mucosal IL-1β concentrations at baseline, 6 months, and the change from baseline to 6 months, stratified by treatment arm (placebo vs. curcumin), including both gastric antrum and corpus samples.
Authors: Maria Gonzalez-Pons, Ricardo L. Dominguez, Eleazar E. Montalvan-Sanchez, Nathan R. Foster, Carrie A. Strand, Jessica Hernandez-Marrero, Dalton A. Norwood, Ryan P. McMurray, Keila L. Rivera Roman, Hilmaris Centeno-Girona, Aida Rodriguez-Murillo, Fatme Ghandour, Sameer Al Diffalha, N Jewel Samadder, Asad Umar, Ellen Richmond, Luz Maria Rodriguez, Paul J. Limburg, Douglas R. Morgan, Marcia Cruz-Correa
Language: English
Subfield: Molecular Medicine
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W7166877468